Pfizer (PFE) Current Assets (2009 - 2026)

Pfizer (PFE) has reported Current Assets for 18 consecutive years, with $41.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 5.37% year-over-year to $41.4 billion in Q2 2026; TTM through Jun 2026 was $41.4 billion, a 5.37% decrease from a year earlier, with the FY2025 full-year figure at $42.9 billion, down 14.81% from the prior year.
• Current Assets was $41.4 billion for Q2 2026 at Pfizer, down from $42.8 billion in the prior quarter.
• Over five years, Current Assets peaked at $73.3 billion in Q3 2023 and troughed at $5.9 billion in Q3 2023.
• A 5-year average of $43.8 billion and a median of $43.5 billion in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 89.75% in 2022 and jumped 635.59% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $51.3 billion in 2022, then declined by 15.46% to $43.3 billion in 2023, then climbed by 16.21% to $50.4 billion in 2024, then retreated by 14.81% to $42.9 billion in 2025, then dropped by 3.59% to $41.4 billion in 2026.
• The last three Current Assets figures came in at $41.4 billion (Q2 2026), $42.8 billion (Q1 2026), and $42.9 billion (Q4 2025), per Business Quant data.